East Tennessee State University

Digital Commons @ East Tennessee State University
ETSU Faculty Works

Faculty Works

1-1-2013

Stability of Extemporaneously Prepared
Lansoprazole Suspension at Two Temperatures
Jordan T. Morrison
East Tennessee State University

Ralph A. Lugo
East Tennessee State University, lugo@etsu.edu

Jim C. Thigpen
East Tennessee State University, thigpen@etsu.edu

Stacy D. Brown
East Tennessee State University, browsd03@etsu.edu

Follow this and additional works at: https://dc.etsu.edu/etsu-works
Citation Information
Morrison, Jordan T.; Lugo, Ralph A.; Thigpen, Jim C.; and Brown, Stacy D.. 2013. Stability of Extemporaneously Prepared
Lansoprazole Suspension at Two Temperatures. Journal of Pediatric Pharmacology and Therapeutics. Vol.18(2). 122-127.
https://doi.org/10.5863/1551-6776-18.2.122 ISSN: 1551-6776

This Article is brought to you for free and open access by the Faculty Works at Digital Commons @ East Tennessee State University. It has been
accepted for inclusion in ETSU Faculty Works by an authorized administrator of Digital Commons @ East Tennessee State University. For more
information, please contact digilib@etsu.edu.

Stability of Extemporaneously Prepared Lansoprazole Suspension at Two
Temperatures
Copyright Statement

This document was published with permission by the editor. It was originally published in Journal of Pediatric
Pharmacology and Therapeutics.

This article is available at Digital Commons @ East Tennessee State University: https://dc.etsu.edu/etsu-works/5315

JPPT
Clinical Investigation
Stability of Extemporaneously Prepared Lansoprazole Suspension at
Two Temperatures
Jordan T. Morrison, PharmD,1 Ralph A. Lugo, PharmD,2 Jim C. Thigpen, PharmD,2 and Stacy D. Brown, PhD1
Departments of 1Pharmaceutical Sciences and 2Pharmacy Practice, East Tennessee State University, Johnson City,
Tennessee

OBJECTIVE The purpose of this study was to examine the stability of a generic lansoprazole product in a 3
mg/mL sodium bicarbonate suspension under room temperature and refrigerated conditions.
METHODS Lansoprazole suspensions (3 mg/mL) were prepared in triplicate using an 8.4% sodium bicarbonate vehicle for each storage condition (room temperature and refrigerated). During 1 month, samples from
each replicate were periodically removed and analyzed for lansoprazole concentration by liquid chromatography–tandem mass spectrometry (LC-MS/MS). Each sample was spiked with 10 mg/L omeprazole to serve
as the internal standard. A positive electrospray LC-MS/MS method was validated over the calibration range
of 5 to 25 mg/L using Food and Drug Administration Guidance. The identities of the analyte and internal
standard in the samples were verified by monitoring the MS/MS transitions of m/z 370 to m/z 252 and m/z
346 to m/z 198 for lansoprazole and omeprazole, respectively. Additionally, the pH of the suspensions was
monitored throughout the study.
RESULTS The stability of lansoprazole in the oral sodium bicarbonate suspension under refrigeration is compromised prior to what has been previously reported in the literature. Samples kept at room temperature lost
>10% of the lansoprazole after 48 hours compared with the refrigerated samples, which maintained integrity
up to 7 days. No statistically significant difference was found between the pH of the room temperature and
refrigerated suspension samples, indicating that this factor is not the cause for the differences in stability
at these two conditions.
CONCLUSIONS This study suggests that the extemporaneously compounded lansoprazole oral suspension
prepared in 8.4% sodium bicarbonate should not be stored in plastic oral syringes longer than 48 hours at
room temperature and no longer than 7 days when refrigerated. These data indicate an expiration time
earlier than that previously reported for the refrigerated product (14 days).
INDEX TERMS drug stability, lansoprazole, suspensions
J Pediatr Pharmacol Ther 2013;18(2):122–127

INTRODUCTION
Proton pump inhibitors (PPIs) are medications
that decrease the amount of acid produced by
gastric parietal cells via the inhibition of the H+/
K+ ATPase enzyme system. Uses for this class
include gastroesophageal reflux disease, prevention of stress-induced ulcers, and treatment of
Barrett esophagus, in adults. Lansoprazole has an
indication for treating pediatric patients (ages 1-11
years) but lacks established safety or effectiveness
data for children younger than 1 year. Even without the data for use in the neonatal population,
PPI use has become routine. The North American
Society for Pediatric Gastroenterology, Hepatol122

ogy and Nutrition and the European Society for
Pediatric Gastroenterology, Hepatology, and Nutrition recommend the use of PPIs in neonates (>3
days and without complications) for the treatment
of gastroesophageal reflux.1
Aside from the dearth of safety and effectiveness information, another obstacle in using PPIs
in neonatal and pediatric patients is the vehicle
of administration. Commonly, adults using PPIs
will receive the medication in a capsule form, but
this is not always practical for younger patients.
Suspensions are often used in these populations
for PPI administration. In a prospective study
performed by Lugo et al,2 that included 21 children’s hospitals, an oral suspension of lansopraJ Pediatr Pharmacol Ther 2013 Vol. 18 No. 2 • www.jppt.org
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zole was the number one reported extemporaneous formulation prepared in the inpatient setting.
In the study, 19 of 21 hospitals surveyed reported
using a 3 mg/mL lansoprazole oral suspension;
however, there are limited data regarding the
stability of this formulation.2
Olabisi et al3 examined preparations of lansoprazole for nasogastric tube administration.
The study included lansoprazole mixed with a
variety of vehicles, including apple juice, cranberry juice, ginger ale, orange juice, water, and
sodium bicarbonate 8.4%. The suspensions were
then passed through a nasogastric (NG) tube and
collected in a graduated cylinder. Of all of the
tested vehicles, sodium bicarbonate 8.4% was
the only one found to provide complete drug retrieval after administration through the NG tube.
Lansoprazole mixed with sodium bicarbonate
8.4% was also the only tested combination that
did not result in any clogging in the NG tube, but
despite this, the manufacturer still recommends
the use of apple juice for NG tube administration of Prevacid.3,4 An alternative formulation
of lansoprazole in Ora-Blend has been recently
proposed by Melkoumov et al,5 yet the stability
is limited to 3 days under refrigeration.
Preparing lansoprazole suspension in the 8.4%
sodium bicarbonate vehicle, known as simplified
lansoprazole suspension (SLS), is the historical
standard6; however, studies examining the stability of the drug in this basic suspension are
conflicting. According to a study by DiGiacinto
et al,7 the reported stability of lansoprazole suspension was 8 hours at 22°C and 14 days at 4°C.
In contrast, a study performed by Phillips et al8
revealed a stability of 4 weeks when lansoprazole
was stored in amber plastic vials under refrigeration and 2 weeks at room temperature. Thus,
the commonly accepted stability of lansoprazole
suspension prepared in 8.4% sodium bicarbonate is 14 days if kept refrigerated.9 The objective
of this study was to verify the stability (NLT
90% and NTM 110% of the labeled amount)10
of a lansoprazole suspension at both room and
refrigerated temperatures.

MATERIALS AND METHODS
Instrumentation and Calibration
Previously published ultra-high-pressure liquid
chromatography–tandem mass spectrometry
methodology was used to analyze all stability
J Pediatr Pharmacol Ther 2013 Vol. 18 No. 2 • www.jppt.org
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study samples for lansoprazole concentration.11
This method was developed and validated according to Food and Drug Administration guidelines for bioanalytical methods.12,13 During each
day of the study, fresh calibration standards using
USP reference standards were prepared in 50:50
v/v water-methanol mixture. The calibration
curve consisted of 5 points: 5, 10, 15, 20, and 25
mg/L lansoprazole. Each calibration and validation solution contained 10 mg/L omeprazole. The
calibration curves used in the study displayed
a linear response in the aforementioned range
with a slope of 0.08596 ± 0.00709, a y-intercept of
0.3525 ± 0.0429, and an R2 value of 0.9931 ± 0.0284.
Quantification was performed using the peak area
ratios between lansoprazole and omeprazole.
Stability Study
Lansoprazole suspension (3 mg/mL) was prepared in triplicate for both refrigerated (3ºC-4oC)
and room temperature (20ºC-22ºC) storage. The
suspensions were made by emptying the contents
of ten 30-mg generic capsules of lansoprazole into
an Erlenmeyer flask and adding 100 mL of 8.4%
sodium bicarbonate solution. The suspensions
were then stirred on a magnetic stir plate for 30
minutes and protected from light. Following this,
the density of each bulk preparation at room temperature was determined using 10-mL samples
in a 10-mL graduate cylinder. This 10-mL sample
of each was retained for baseline pH determination. Thereafter, 0.6-mL aliquots of suspension
were drawn up into plastic amber-colored oral
syringes to be stored under the 2 test conditions.
Syringes were removed for each time point, the
contents were diluted with 8.4 mL of a 50:50 mix
of methanol and water, and they were vortex
mixed. From this mixture, 100 µL was removed
by micropipette and further diluted with 800 µL
of the 50:50 solvent mixture. A volume of 100 µL of
the internal standard (100 mg/L omeprazole) was
added to the aforementioned mixture for a final
concentration of 10 mg/L omeprazole. The final
dilution of lansoprazole was intended to bring
the sample concentration within the calibration
range (5-25 mg/L). The actual concentration of
lansoprazole in each sample was calculated using
the calibration curve from that day. Suspension
samples were filtered via a 0.22-µm filter prior to
being added to the autosampler vials.
For each sampling time point, the filled and
empty syringes were weighed so as to correct for
123

JPPT

JT Morrison, et al

Table. Stability of Lansoprazole up to 90 Days at Room Temperature (20ºC -22ºC) and Refrigerated Temperature (3ºC4ºC) Expressed as Mean Concentration (mg/mL) ± SD and Percent Remaining From Initial Concentration (Time 0 Hours),
n=12, for Each Condition at Each Time Point, Determined by LC-MS/MS Using Omeprazole as an Internal Standard*
Storage
0 hr
20ºC-22ºC
3ºC-4ºC

2 hr

4 hr

Time Since Compounding
6 hr
8 hr

12 hr

24 hr

48 hr

2.70 ± 0.23, 2.60 ± 0.14, 2.59 ± 0.21, 2.55± 0.39, 2.45 ± 0.25, 2.49 ± 0.24, 2.47 ± 0.28, 2.45 ± 0.28,
100
96.0
95.9
94.4
90.7
92.2
91.2
90.8
2.82 ± 0.16, 2.78 ± 0.30, 2.78 ± 0.12, 2.74 ± 0.40, 2.71 ± 0.11, 2.68 ± 0.16, 2.67 ± 0.14, 2.65 ± 0.14,
100
98.6
99.1
97.1
96.1
95.0
94.6
94.0

*Values given are displayed as: mean lansoprazole concentration (mg/mL) ± SD, percent deviation from initial concentration (concentration at time 0 hours)

density differences between the replicate preparations. This strategy of using the weight of the
suspension sample instead of the volume alone
has been previously demonstrated as an effective
way to compensate for the error involved in sampling a non-homogeneous matrix.14 At each time
point, 2 samples were taken from each replicate,
and each sample was injected twice for a total of 4
injections at each time point. Additional samples
were analyzed from the bulk suspensions at time
0 hours and at 7, 14, and 30 days to assess the
impact of storage in the oral syringes. Finally,
the pH of the preparations was monitored at 0
hours and at 7, 14, 21, and 30 days.
Data Analysis
The stability of lansoprazole in the oral suspension preparations was assessed by comparing
the percentage of drug remaining at each time
point to the initial concentration. Statistical
analyses were performed using GraphPad Prism
software (GraphPad Software, La Jolla, CA). Additionally, 1-way analysis of variance (ANOVA;
p<0.05) with a Dunnett posttest was used to
verify statistically significant degradation. The
degradation constant (k) was determined from
linear regression data of each replicate, assuming first-order kinetics, because the first-order
degradation model fit the data better than zero
or second order. Using the degradation constants
from each temperature condition, the frequency
factor and activation energy of degradation were
calculated using the Arrhenius equation.8 Additional analyses included verification that the
replicates within each temperature condition
were not statistically different using a repeatedmeasures ANOVA (p<0.05) and a Bonferroni
posttest. The pH measurements between the 2
conditions were also compared using a 2-tailed
124

Student t-test (p<0.05). Finally, to evaluate the impact of storing the samples in oral syringes versus
the bulk suspension, these data were compared
using a 1-way ANOVA with Bonferroni multiple
comparison test (p<0.05).

RESULTS
Room Temperature Samples Versus Refrigerated
Samples
The Table shows the degradation profiles of
the lansoprazole suspensions at refrigerated and
room temperature conditions. Under refrigeration, the drug concentration in the suspension
first dipped below 90% at the 8-day time point,
and at 72 hours for room temperature samples.
This indicates a beyond-use date of 7 days (refrigerated) and 48 hours (room temperature)
for SLS prepared with generic lansoprazole.
Statistically significant degradation was verified
using the 1-way ANOVA analysis (p<0.05; 0-hour
concentration as control). Additionally, within
each experimental group the replicates were
not shown to have any statistically significant
differences. Statistically significant pairing was
noted in both groups, with R2 = 0.9293 in the
refrigerated group and R2 = 0.8794 among the
room temperature replicates.
Degradation Kinetics
Various concentration-versus-time plots were
examined for the combination of replicates from
each condition, and it was determined that
first-order kinetics was the best fit. Using the
degradation rate constant (k) for each replicate at
each condition, the frequency factor (A) and the
activation energy (Ea) were determined from the
Arrhenius equation, resulting in A = 17,354 hr−1
and Ea = 26.5 kJ/mol. The mean rate constants
J Pediatr Pharmacol Ther 2013 Vol. 18 No. 2 • www.jppt.org
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Table. Stability of Lansoprazole up to 90 Days at Room Temperature (20ºC -22ºC) and Refrigerated Temperature (3ºC4ºC) Expressed as Mean Concentration (mg/mL) ± SD and Percent Remaining From Initial Concentration (Time 0 Hours),
n=12, for Each Condition at Each Time Point, Determined by LC-MS/MS Using Omeprazole as an Internal Standard* (cont.)
Storage
20ºC-22ºC
3ºC-4ºC

72 hr

96 hr

2.37 ± 0.17,
87.7
2.63 ± 0.29,
93.1

2.38 ± 0.21,
87.9
2.62 ± 0.16,
92.7

Time Since Compounding
7 days
8 days
14 days
2.34± 0.25,
86.7
2.55± 0.25,
90.5

2.34 ± 0.30,
86.6
2.50 ± 0.18,
88.5

2.37 ± 0.07,
87.8
2.53 ± 0.26,
89.8

21 days

30 days

2.27 ± 0.17,
84.1
2.46 ± 0.18,
87.2

2.27 ± 0.25,
83.8
2.43 ± 0.17,
86.0

*Values given are displayed as: mean lansoprazole concentration (mg/mL) ± SD, percent deviation from initial concentration (concentration at time 0 hours)

for the refrigerated replicate were 0.000187 and
0.000179 hr−1 for the samples stored under room
temperature.
Stability of pH
Sample pH was periodically monitored
throughout the study. Refrigerated samples held
a pH of 8.579 ± 0.118 (average ± SD; n=15), whereas the room temperature sample pH was 8.578
± 0.127 (n=15). No statistically significant difference in these data was detected using a 2-tailed
Student t-test (p<0.05) with an R2 of 3.294e-005,
and the relative SD of these measurements was
less than 1.5% for each group. This indicates that
pH was not a factor in the drug degradation and
that the 8.4% sodium bicarbonate was sufficient
to maintain pH past the beyond-use time for both
temperature conditions.
Impact of Density Correction
Using a density correction to compensate for
sampling from a non-homogeneous mixture
has been shown to be effective in previous
studies on omeprazole stability.14 The error that
is compensated for by this density correction
ranges from 0.82% to 17.3%, with a 6.95% mean
deviation between the data that were corrected
for the weight/density of the sample versus
that which were not. The replicates that were
refrigerated had a density of 1.073 ± 0.054 (mean
± SD; n = 3), and the room temperature ones had
a density of 1.033 ± 0.0052 (n=3). Furthermore,
the densities of these 2 groups of preparations
were compared using an unpaired, 2-tailed t-test,
and the means were not found to be statistically
different (p<0.05).
Impact of Storage in Syringes Versus Bulk Bottles
Finally, the results from the suspension samples stored in amber syringes were compared
J Pediatr Pharmacol Ther 2013 Vol. 18 No. 2 • www.jppt.org

with a limited number of sampling points from
the bulk (amber-colored) plastic bottles of each
replicate. The calculated concentration of lansoprazole at 168-, 336-, and 720-hour time points
was compared between the bulk bottles and
corresponding oral syringes for each replicate;
however, no statistically significant difference
was detected (p<0.05).

DISCUSSION
Use of Liquid Chromatography–Tandem Mass
Spectrometry Technology to Study Drug Stability
Most published drug stability studies use
high-performance liquid chromatography with
ultraviolet detection for quantification of the
drug of interest. In this study, we employed a
more sensitive and specific methodology, liquid
chromatography–tandem mass spectrometry
(LC-MS/MS), because of the concerns regarding
rapid degradation of lansoprazole. Unlike ultraviolet detection, mass spectrometric detection
correlates to the specific molecular weight of a
compound, and with our instrument this molecular weight is accurate out to 0.0001 mass units.
This specificity ensures that the chromatographic
peak being monitored is in fact that of the drug
of interest—in this case lansoprazole—and not
a degradation product. Specificity is ensured by
monitoring an ion channel specific to the molecular weight of lansoprazole (m/z 370).
Density Correction in Data Analysis
The impact of our correcting for the mass
of each of the samples in this study cannot be
overstated. When samples from this non-homogeneous suspension are removed by volume,
even with a wide-opening pipette tip, their individual contents can vary greatly. Rather than
relying on pipette volume to calculate lansopra125
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zole concentration in the samples, we used the
sample weight and determined the true volume
withdrawn using density of each replicate. The
precedent for this practice has been set,14 and we
found it to be an effective way to compensate
for sampling from non-homogeneous mixtures.
This also removes the need for timed shaking for
resuspension prior to sampling.
Initial Lansoprazole Concentration
The recipe used for compounding SLS reports
an initial concentration of 3 mg/mL, which is
expected following complete release of drug from
polymer microspheres and 100% dissolution if
300 mg of drug were dissolved in 100 mL of vehicle. However, previous studies have indicated
limitations in the dissolution of lansoprazole in
sodium bicarbonate, suggesting that Ora-Blend
may be a more suitable vehicle for this preparation.5 Because of this, we determined an initial,
time-0 hours, concentration of each replicate to
serve as the reference against which the beyonduse date was calculated. This practice is common
in stability investigations because this starting
concentration will vary slightly among individual
preparations.15–18 Nevertheless, our preparations
recovered a mean of 90.3% (room temperature
replicates) and 94.2% (refrigerated replicates) relative to the theoretical concentration of 3 mg/mL.
Directions for Future Stability Investigations
Work by Ensom et al19 indicates the stability of
lansoprazole in oral suspension can be retained
up to 90 days if stored in glass containers. In this
study, they also address the important issue of
not only a stable preparation, but also a palatable
one, showing that the traditional SLS is highly
undesirable for oral administration, restricting
its use to NG administration.19 Future investigation is called for that looks at the interactions
this drug has with plastic matrices, with regard
to storage in plastic prescription bottles, in oral
syringes, and administration through NG tubes.
Additionally, the practice of reserving all stability
study samples at −80oC so they can be analyzed
on the same day has the potential to reduce error
associated with intraday variations.19

CONCLUSION
The results of this study indicate that lansoprazole suspension (3 mg/mL) loses stability,
126

as defined by >10% reduction of the initial concentration, at 48 hours under room temperature
conditions and after 7 days under refrigerated
conditions. These study samples were stored in
amber-colored oral syringes to protect the drug
from light as well as to ensure ease of sampling
during the study. The results of this study indicate that the stability of lansoprazole suspension
under refrigeration is shorter than previously
recognized, if stored in plastic oral syringes.
However, this study shows that the 8.4% sodium
bicarbonate vehicle is sufficient to maintain the
pH of this drug preparation past the beyonduse time, and that storage in amber-colored oral
syringes results in stability comparable to that
of storage in bulk amber-colored plastic bottles,
regardless of temperature. Suspension palatability was not assessed. Finally, the use of density
correction to account for differences among nonhomogeneous preparations such as SLS allows
for more accurate quantification of the drug in
small sample volumes.
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